VISTN Vistin Pharma ASA

Vistin Pharma ASA: Third quarter and YTD 2022 financial results

Vistin Pharma ASA: Third quarter and YTD 2022 financial results

Oslo, Norway, 26th of October 2022

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the third quarter 2022

Strong revenue growth in the quarter compared to last year. Revenue in the third quarter ended at MNOK 92 compared to MNOK 63 in Q3 2021, a 46% increase. Sales volume in the quarter was up by 19% compared to same quarter last year. The demand in the market for metformin from Vistin is high. However, there were still limitations on volume available for sale, due to MEP ramp-up activities.

Third quarter EBITDA ended at negative MNOK 2.9 (Q3’21: MNOK 3.8). Volatility with Ukraine situation and European energy prices continues to put pressure on profitability with record high electricity prices and increasing raw material cost (both inflation and USDNOK FX rate). In addition there were a one-time negative cost effect of MNOK 5 in quarter in relation to non-sellable validation batches from the new production line and inventory adjustment.

The net profit ended at negative MNOK 6.7 (Q3’21: MNOK 0.9) for the third quarter of 2022.

Continued process optimizations resulted in close to 1100MT production volume which is a new quarterly record. Installed capacity at end Q3 is close to 5000MT and is expected to continue to improve gradually during Q4 to reach an annual capacity of >5 500MT by end 2022. Annual capacity of close to 7000MT expected to be reached by 2023

Vistin Pharma had net debt of MNOK 38 (Q3’21 net cash MNOK: 52) as of 30 September 2022. Driven by volume-ramp up, increased raw material stocks and time from production start of line #2 to payment from customers, the working capital requirements in Q3 has been high. The operational cash flow is expected to improve from Q4. A revolving credit facility has been established to handle planned liquidity effects from ongoing expansion and investments.

Approx. 85% of the Metformin Expansion Project (MEP) has been paid as of end September and project cost is according to budget.

The third quarter conference call, which will be held today, 26th of October, at 8.30am (CET), will be available via webcast and audio through the following access points:

Webcast:

Telephone conference (online registration):

The conference call will be held in English.    

Please find the Q3 report and presentation enclosed. The report will also be made available on .

*****

For further information, please contact:

Alexander Karlsen

CFO

 36 21

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

 

 

Attachments



EN
26/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vistin Pharma ASA

 PRESS RELEASE

Vistin Pharma ASA: Mandatory notification of trade

Vistin Pharma ASA: Mandatory notification of trade Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.   Attachment

 PRESS RELEASE

Vistin Pharma ASA (VISTN): Key information relating to the proposed ca...

Vistin Pharma ASA (VISTN): Key information relating to the proposed cash dividend The Board of Directors will propose for the AGM to get a power of attorney to pay-out an ordinary cash dividend of up to NOK 1.50 per share, to be paid partly with NOK 1 in May and up to NOK 0.50 in November, for the accounting year of 2025. The formal decision regarding the dividend will be made on the company's Annual General Meeting, which will be held on 20 May 2026. Dividend amount (per share): NOK 1 Declared currency: NOK Last day including right: 21 May 2026 Ex-date: 22 May 2026 Record date: 26 May...

 PRESS RELEASE

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial resul...

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a record year for Vistin Pharma with all-time high revenue and EBITDA. Revenue in the fourth quarter ended at MNOK 111 compared to MNOK 114 in Q4 2024. Record high sales volume in quarter (+9%), offset by lower global metformin prices compared to same quarter last year. 2025 full year revenue ended at all-time high MNOK 452 com...

 PRESS RELEASE

Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call

Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call Oslo, Norway, 5 February 2026 Vistin Pharma ASA will release its fourth quarter and preliminary 2025 results on Thursday 12th of February 2025. Vistin Pharma will host a conference call for all shareholders and interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The fourth quarter conference call will be available via web and audio through the following access points: Webcast: Telephone conference (online registrati...

 PRESS RELEASE

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8% Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 28 positively affe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch